DUBLIN--(BUSINESS WIRE)--The "Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030" report has been added to ResearchAndMarkets.com's offering.
The Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030' report features an extensive study of the market for novel drugs, drug-device combinations and technologies for the treatment of back of the eye disorders. The focus of this study is on the applications and the likely evolution of novel treatment options (excluding steroids and corticosteroids) in the mid to long term.
According to the World Health Organization, close to 250 million individuals, including 36 million blind people, presently suffer from some form of vision impairment. Further, a recent study published in September 2017 estimates that the number of blind people is likely to increase to 38.5 million, by 2020, and to 115 million, by 2050. Current projections also indicate that, in the US alone, the total economic burden related to vision loss is expected to reach approximately USD 715 billion by 2050.
In fact, chronic eye diseases are considered to be one of the main causes of vision loss globally, and an estimated 90% cases of visual impairment are reported to be caused due to such conditions. It is worth highlighting that a significant portion of these chronic ophthalmological disorders are clinical conditions related to the back of the eye.
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2017-2030. To account for the uncertainties associated with the development of novel drugs and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.
Key Topics Covered:
2. Executive Summary
4. Competitive Landscape
5. Product Life Cycle Management Strategies
6. Drug Profiles
7. Market Size And Opportunity Analysis
8. Technology Platforms, Delivery Systems And Drug Device Combinations
9. Visual Prosthesis
10. Partnerships And Collaborations
11. Promotional Analysis
12. Swot Analysis
14. Interview Transcripts
15. Appendix: List Of Discontinued Molecules
16. Appendix: Tabulated Data
17. Appendix: List Of Companies And Organizations
For more information about this report visit https://www.researchandmarkets.com/research/lmqbxx/back_of_the_eye?w=4